Cuban biotechnology stands out at World Immunology Congress

Cuba’s scientific expertise in treating autoimmune diseases was showcased at the plenary session of the 19th International Congress of Immunology, taking place in Vienna until August 22.

The event is sponsored by the International Union of Immunological Societies.

Cuban Doctor of Sciences María del Carmen Domínguez, head of the Autoimmunity and Inflammation project at the Center for Genetic Engineering and Biotechnology, outlined the advancements in the Jusvinza medication.

Developed in Cuba for the treatment of rheumatoid arthritis, this drug has also been authorized for the management of severe COVID-19 cases within the country.

The expert elucidated the scientific basis for Jusvinza's design, as well as the evidence supporting its mechanism of action through the induction of immunological tolerance.

The presentation sparked significant interest among the international community, which acknowledges the pivotal role played by Cuban institutions such as the Center for Genetic Engineering and Biotechnology, the Molecular Immunology Center, and the Finlay Vaccine Institute in the development of cutting-edge medical solutions.

Cuba's involvement in this forum underscores its commitment to advanced biomedical research and to global health solidarity.